Effect of Aromatase Inhibitors on Lipid Metabolism, Inflammatory Response and Antioxidant Balance in Patients with Breast Carcinoma

Background: Aromatase inhibitors may affect lipid metabolism, inflammatory response and antioxidant balance. Patients and Methods: One hundred and eighty-six post-menopausal patients with breast carcinoma underwent evaluation of parameters of lipid metabolism, inflammatory response and antioxidant b...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2009-08, Vol.29 (8), p.3337-3346
Main Authors: MELICHAR, Bohuslav, KALABOVA, Hana, KRCMOVA, Lenka, URBANEK, Lubor, HYSPLER, Radomír, SOLICHOVA, Dagmar, MELICHAROVA, Karolina, PECKA, Miroslav, ZADAK, Zdenek
Format: Article
Language:English
Subjects:
alpha-Tocopherol - blood
Antineoplastic Agents, Hormonal - pharmacology
Aromatase Inhibitors - pharmacology
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
C-Reactive Protein - metabolism
Fibrinogen - metabolism
Gynecology. Andrology. Obstetrics
Humans
Lipoprotein(a) - metabolism
Lipoproteins, LDL - metabolism
Lipoproteins, VLDL - metabolism
Mammary gland diseases
Medical sciences
Neopterin - urine
Prognosis
Prospective Studies
Tamoxifen - pharmacology
Tumors
Vitamin A - blood
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Aromatase inhibitors may affect lipid metabolism, inflammatory response and antioxidant balance. Patients and Methods: One hundred and eighty-six post-menopausal patients with breast carcinoma underwent evaluation of parameters of lipid metabolism, inflammatory response and antioxidant balance immediately before as well as 2 and 4 months after the start of therapy with aromatase inhibitors. Results: A significant increase in total, very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol, lipoprotein (a), retinol, C-reactive protein and fibrinogen was observed. The changes of serum lipid concentrations were restricted mostly to the patients pre-treated with tamoxifen who had significantly lower baseline levels of these parameters. Conclusion: An increase of serum cholesterol, lipoprotein (a), C-reactive protein and fibrinogen in patients treated with aromatase inhibitors is the result of tamoxifen withdrawal rather than a direct effect of therapy. No significant changes in serum lipids were observed in patients treated with aromatase inhibitors in the first-line setting.
ISSN:0250-7005
1791-7530